Updated menopause guidance reassesses hormone therapy

Hormone therapy is getting a new look in menopause care. Updated guidance reported this week says it can be an appropriate first-line option for many people with bothersome hot flashes and night sweats, and it may also help some sleep-related and mood symptoms tied to the menopause transition. The shift does not mean hormone therapy is right for everyone, but it does reflect a broader move away from one-size-fits-all caution. https://www.cbsnews.com/news/menopause-perimenopause-hormone-replacement-therapy-guidelines-acog/

The latest discussion comes as federal regulators have also revisited how menopause hormone products are labeled. In 2025 and 2026, the Food and Drug Administration approved or requested changes to boxed warnings for several menopausal hormone therapy products, saying the language should better reflect the evidence and help patients and clinicians make more informed decisions. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products

What changed

The CBS report says the American College of Obstetricians and Gynecologists has issued new guidance for common menopause and perimenopause symptoms and now recommends hormone replacement therapy for many women with hot flashes and night sweats. The report also says the organization views hormone therapy as first-line treatment for vasomotor symptoms, which include hot flashes, night sweats and related sleep problems. https://www.cbsnews.com/news/menopause-perimenopause-hormone-replacement-therapy-guidelines-acog/

That reported shift matters because menopause treatment has long been shaped by safety concerns from earlier studies and by years of conservative prescribing. The new framing does not erase those concerns. Instead, it suggests clinicians should weigh symptom burden, timing, and individual medical history more carefully when considering treatment. https://www.cbsnews.com/news/menopause-perimenopause-hormone-replacement-therapy-guidelines-acog/

Why it matters for patients

Menopause is a normal biological transition, but symptoms can be disruptive. Hot flashes, night sweats, vaginal dryness and painful sex are among the issues that can affect daily life, sleep and well-being. The FDA says hormone therapy can help relieve hot flashes, night sweats, vaginal dryness and pain with sex, and in some situations it may help prevent bone loss. https://www.fda.gov/consumers/womens-health-topics/menopause

For many people, the practical question is not whether menopause is natural. It is whether symptoms are severe enough to justify treatment, and which treatment is the safest fit. FDA-approved hormone therapies come in several forms, including pills, patches, sprays, gels and vaginal products. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products

What the evidence actually shows

The strongest evidence for menopausal hormone therapy is for symptom relief, especially vasomotor symptoms such as hot flashes and night sweats. FDA materials say these benefits are established, and that hormone therapy may also help vaginal symptoms and reduce bone loss in some situations. https://www.fda.gov/consumers/womens-health-topics/menopause

At the same time, the evidence does not support using hormone therapy to prevent heart disease, stroke or dementia. The FDA explicitly says not to use hormone therapy for those purposes. It also notes that, for some women, hormone therapy can increase the risk of blood clots, heart attacks, strokes, breast cancer and gallbladder disease, and that estrogen alone raises endometrial cancer risk in people with a uterus unless progestin is added. https://www.fda.gov/consumers/womens-health-topics/menopause

Timing appears to matter. FDA labeling updates now advise considering hormone therapy for moderate to severe vasomotor symptoms in women younger than 60 or within 10 years of menopause onset, and the agency says randomized studies show reduced all-cause mortality and fractures when treatment begins within that window. Research reviews in PubMed also support the idea that cardiovascular risk is generally lower when hormone therapy is started closer to menopause rather than many years later. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-requests-labeling-changes-related-safety-information-clarify-benefitrisk-considerations

That does not mean the therapy is risk-free. It means the risk-benefit balance may be different for people who are closer to the menopause transition than for those starting much later. The older “timing hypothesis” remains a framework, not a guarantee, and published reviews still describe ongoing uncertainty about long-term cardiovascular outcomes across different formulations, doses and routes. https://pubmed.ncbi.nlm.nih.gov/30484736/

What remains uncertain

One open question is how much of the benefit comes from symptom control versus broader health effects. Some studies and reviews suggest that earlier use may be safer for the heart than late initiation, but that is not the same as showing hormone therapy should be used to improve long-term cardiovascular health. The evidence is stronger for treating symptoms than for preventing future disease. https://pubmed.ncbi.nlm.nih.gov/30484736/

Another uncertainty is how to translate population-level evidence into an individual decision. The FDA still says some people should not use hormone therapy, including those with certain cancers, a history of blood clots, stroke or heart attack, liver disease, or unexplained vaginal bleeding. CBS also reported that people with a personal history of breast cancer should avoid these therapies, according to the new guidance discussed in the story. https://www.fda.gov/consumers/womens-health-topics/menopause

There is also confusion about compounded or so-called bioidentical hormones. FDA guidance says it does not have evidence that compounded “bioidentical hormones” are safer or more effective than FDA-approved hormone therapy. That distinction matters because approved products are reviewed for safety and effectiveness, while compounded products are not. https://www.fda.gov/consumers/womens-health-topics/menopause

What to discuss with a clinician

For people considering treatment, the most useful discussion is usually not “hormones or no hormones,” but rather which symptoms are most disruptive, what personal risk factors are present, and whether a systemic or local treatment makes sense. FDA-approved hormone therapy may be used in different ways depending on whether symptoms are mainly hot flashes and night sweats, vaginal symptoms, or both. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products

Questions worth bringing up include whether symptoms are interfering with sleep or daily activities, whether the person has a history of blood clots or hormone-sensitive cancer, whether the uterus is present, and whether a lower-dose or vaginal option could address the main concern. The FDA says treatment decisions should be made with a health care provider because there are many different FDA-approved hormones for menopausal symptoms. https://www.fda.gov/consumers/womens-health-topics/menopause

People who have vaginal bleeding after menopause should seek medical attention promptly, since the FDA says that can be a sign of an urgent medical problem. And because hot flashes and sleep disruption can also have other causes, persistent or severe symptoms deserve evaluation rather than self-treatment. https://www.fda.gov/consumers/womens-health-topics/menopause

The bottom line

Updated menopause guidance appears to be moving hormone therapy back toward the center of care for bothersome vasomotor symptoms, especially when treatment begins near the menopause transition. The evidence supports symptom relief, but not using hormones to prevent heart disease, stroke or dementia. As with most menopause decisions, the right choice depends on symptoms, timing and personal risk factors, not on a single rule for everyone. https://www.cbsnews.com/news/menopause-perimenopause-hormone-replacement-therapy-guidelines-acog/